Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial
- Nobile-Orazio, E
- Cocito, D
- Jann, S
- Uncini, A
- Beghi, E
- Messina, P
- Antonini, G
- Fazio, R
- Gallia, F
- Schenone, A
- Francia, A
- Pareyson, D
- Santoro, L
- Tamburin, S
- Macchia, R
- Cavaletti, G
- Giannini, F
- Sabatelli, M
- Nobile-Orazio, E
- Gallia, F
- Cocito, D
- Paolasso, I
- Jann, S
- De Toni Franceschini, L
- Uncini, A
- Notturno, F
- Antonini, G
- Clemenzi, A
- Fazio, R
- Bianchi, F
- Schenone, A
- Fiorina, E
- Francia, A
- Pontecorvo, S
- Pareyson, D
- Marchesi, C
- Santoro, L
- Manganelli, F
- Tamburin, S
- Praitano, Ml
- Cavaletti, G
- Piatti, M
- Giannini, F
- Greco, G
- Sabatelli, M
- Luigetti, M
- Beghi, E
- Messina, P
- Macchia, R
- Guarnieri, C
- Fiorentino, B.
DOIAbstract
Intravenous immunoglobulin (IVIg) and corticosteroids are effective as initial treatment in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but little is known about the comparative risk-benefit profile of their long-term use in this disease. We compared the efficacy and tolerability of 6-month therapy with IVIg versus that with intravenous methylprednisolone
Add to ORKG